Skip to content

Combined expression and significance study of PRL-3, MMP9 in circulating tumor ceils of colorectal cancer

Combined expression and significance study of PRL-3, MMP9 in circulating tumor ceils of colorectal cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RDD-16007819
Enrollment
Unknown
Registered
2016-01-24
Start date
2016-01-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oncology

Interventions

Sponsors

Affiliated hospital of Guangdong Medicine College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: We will collect and record the follow-up data from each into-group colorectal cancer patients,who cames from the 40-70 cases that grouped by pathological diagnosis of phase I, II, III to surgery. Capture and identify circulating tumor cells in colorectal cancer through Canpatrol TM second generation CTC technology, which is a novel CTC capture and identification technology. And using RNA ISH method to detect the quantitative expression of single target gene. The data of express quantity will be statistical analyzed according to the internal gene expression. Through Image J software, analysis the fluorescent signal of high, medium and low internal gene expression from a large number of CTC samples,and set the different gene expression intensity of fluorescence signal distribution areas. After analyzing the purpose gene fluorescence signal of CTC samples to be detected by Image J software,the purpose gene expression intensity analysis can be taken with high, medium and low internal gene fluorescence signal distribution area for reference.After that, track patients, and analyze the relapse metastasis differences of patients with the different expression.

Exclusion criteria

Exclusion criteria: colorectal cancer patients of phase IV

Design outcomes

Primary

MeasureTime frame
Survival analysis;

Countries

China

Contacts

Public ContactLiang Qilian
13822522910@163.com+86 13822522910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026